Dyne Therapeutics annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics Capital Expenditures (CapEx) Growth & History (DYN)
Dyne Therapeutics's capital expenditures (capex) was $1.9M for fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.9M | −$456,000 | −19.19% |
| 2024 | 2024-12-31 | $2.4M | $1.6M | +225.93% |
| 2023 | 2023-12-31 | $729,000 | −$2.3M | −76.23% |
| 2022 | 2022-12-31 | $3.1M | −$551,000 | −15.23% |
| 2021 | 2021-12-31 | $3.6M | $2.5M | +211.63% |
| 2020 | 2020-12-31 | $1.2M | −$486,000 | −29.51% |
| 2019 | 2019-12-31 | $1.6M | — | — |
Dyne Therapeutics quarterly capital expenditures (capex)
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.5M | $1.5M | +2423.33% |
| Q1 2026 | 2026-03-31 | $221,000 | −$760,000 | −77.47% |
| Q4 2025 | 2025-12-31 | $484,000 | −$591,000 | −54.98% |
| Q3 2025 | 2025-09-30 | $395,000 | $142,000 | +56.13% |
| Q2 2025 | 2025-06-30 | $60,000 | −$797,000 | −93.00% |
| Q1 2025 | 2025-03-31 | $981,000 | $790,000 | +413.61% |
| Q4 2024 | 2024-12-31 | $1.1M | $993,000 | +1210.98% |
| Q3 2024 | 2024-09-30 | $253,000 | $86,000 | +51.50% |
| Q2 2024 | 2024-06-30 | $857,000 | $607,000 | +242.80% |
| Q1 2024 | 2024-03-31 | $191,000 | −$39,000 | −16.96% |
| Q4 2023 | 2023-12-31 | $82,000 | −$437,000 | −84.20% |
| Q3 2023 | 2023-09-30 | $167,000 | −$719,000 | −81.15% |
| Q2 2023 | 2023-06-30 | $250,000 | −$11,000 | −4.21% |
| Q1 2023 | 2023-03-31 | $230,000 | −$1.2M | −83.58% |
| Q4 2022 | 2022-12-31 | $519,000 | −$1.5M | −73.92% |
| Q3 2022 | 2022-09-30 | $886,000 | $5,000 | +0.57% |
| Q2 2022 | 2022-06-30 | $261,000 | −$477,000 | −64.63% |
| Q1 2022 | 2022-03-31 | $1.4M | $1.4M | +15466.67% |
| Q4 2021 | 2021-12-31 | $2.0M | $1.3M | +175.24% |
| Q3 2021 | 2021-09-30 | $881,000 | $725,000 | +464.74% |
| Q2 2021 | 2021-06-30 | $738,000 | $667,000 | +939.44% |
| Q1 2021 | 2021-03-31 | $9,000 | −$202,000 | −95.73% |
| Q4 2020 | 2020-12-31 | $723,000 | — | — |
| Q3 2020 | 2020-09-30 | $156,000 | — | — |
| Q2 2020 | 2020-06-30 | $71,000 | — | — |
| Q1 2020 | 2020-03-31 | $211,000 | — | — |
Dyne Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Dyne Therapeutics's capital expenditures (capex) increased from $1.2M to $1.9M, a change of $759,000. The latest reported quarter, Q2 2026, shows $1.5M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...